HIIT With an Eccentric Hamstring Exercise Program in Futsal Players

May 2, 2023 updated by: University of Valencia

Effects of High-intensity Interval Training With an Eccentric Hamstring Exercise Program in Futsal Players

Physiotherapy protocols based on high-intensity interval training (HIIT) or eccentric hamstring exercises like Nordic Curl (NC) have been scarcely studied in futsal players. The hypothesis of this study is that a HIIT combined with an NC exercise program is more effective than a HIIT-only program in improving physical and functional characteristics in futsal players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The objective of this study was to compare the effectiveness of a HIIT combined with an NC exercise program versus a HIIT-only program in futsal players. Therefore, a randomized controlled trial will be carried out. Futsal players will be divided into 1) HIIT+NC group and 2) HIIT group. The HIIT+NC group will perform a HIIT circuit combined with 3 sets of 10 NC repetitions for 4 weeks, while the HIIT group will perform the same protocol without NC exercise. BMI, intermittent work performance, vertical jump performance without and with arms, isometric strength of quadriceps and hamstrings, and the isometric H/Q ratio, will be assessed before and after the interventions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
21

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Valencia, Spain, 46010
        • University of Valencia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Futsal players, over 18 years of age.

Exclusion Criteria:

  • Those who had a medical condition that prevented them from performing any of the evaluations.
  • Those who declined to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: HIIT and Nordic Curl exercise group
The participants will perform a weekly 50 minutes session for four weeks.
Other: HIIT and Nordic Curl exercise program
The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
Active Comparator: HIIT-only group
The participants will perform a weekly 40 minutes session for four weeks.
Other: HIIT-only program
The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Intermittent work performance
Time Frame: Baseline
Intermittent work performance will be assessed with the 30x15 Intermittence Test (30x15IFT). The speed of the test will be recorded in km/h. The higher the speed achieved, the better work performance.
Baseline
Intermittent work performance
Time Frame: After the intervention (4 weeks)
Intermittent work performance will be assessed with the 30x15 Intermittence Test (30x15IFT). The speed of the test will be recorded in km/h. The higher the speed achieved, the better the work performance.
After the intervention (4 weeks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Vertical jump performance without arm impulse
Time Frame: Baseline
Vertical jump performance without arm impulse will be measured with the Counter Movement Jumping Test (CMJ). The jump height was calculated using the My Jump 2 program (My Jump Lab, Madrid, Spain) in cm. The higher the height achieved, the better the vertical jump performance.
Baseline
Vertical jump performance without arm impulse
Time Frame: After the intervention (4 weeks)
Vertical jump performance without arm impulse will be measured with the Counter Movement Jumping Test (CMJ). The jump height was calculated using the My Jump 2 program (My Jump Lab, Madrid, Spain) in cm. The higher the height achieved, the better the vertical jump performance.
After the intervention (4 weeks)
Vertical jump performance with arm impulse
Time Frame: Baseline
Vertical jump performance with arm impulse will be measured with the Counter Movement Jumping Test (CMJ). The jump height was calculated using the My Jump 2 program (My Jump Lab, Madrid, Spain) in cm. The higher the height achieved, the better the vertical jump performance.
Baseline
Vertical jump performance with arm impulse
Time Frame: After the intervention (4 weeks)
Vertical jump performance with arm impulse will be measured with the Counter Movement Jumping Test (CMJ). The jump height was calculated using the My Jump 2 program (My Jump Lab, Madrid, Spain) in cm. The higher the height achieved, the better the vertical jump performance.
After the intervention (4 weeks)
Maximal quadriceps isometric strength
Time Frame: Baseline
Maximal quadriceps isometric strength will be measured using the Adapted Quadriceps Sphygmomanometer Test in mmHg. The higher the pressure (mmHg) achieved, the better the quadriceps isometric strength.
Baseline
Maximal quadriceps isometric strength
Time Frame: After the intervention (4 weeks)
Maximal quadriceps isometric strength will be measured using the Adapted Quadriceps Sphygmomanometer Test in mmHg. The higher the pressure (mmHg) achieved, the better the quadriceps isometric strength.
After the intervention (4 weeks)
Maximal hamstrings isometric strength
Time Frame: Baseline
Maximal hamstrings isometric strength will be measured using the Adapted Hamstrings Sphygmomanometer Test in mmHg. The higher the pressure (mmHg) achieved, the better the hamstrings isometric strength.
Baseline
Maximal hamstrings isometric strength
Time Frame: After the intervention (4 weeks)
Maximal hamstrings isometric strength will be measured using the Adapted Hamstrings Sphygmomanometer Test in mmHg. The higher the pressure (mmHg) achieved, the better the hamstrings isometric strength.
After the intervention (4 weeks)
Isometric hamstrings/quadriceps ratio
Time Frame: Baseline
Isometric hamstrings/quadriceps (H/Q) ratio will be calculated by dividing the values obtained previously in the maximum isometric strength test of the hamstrings by those obtained in the quadriceps test. The value closer to 1, the greater the balance between the hamstrings and quadriceps muscles.
Baseline
Isometric hamstrings/quadriceps ratio
Time Frame: After the intervention (4 weeks)
Isometric hamstrings/quadriceps (H/Q) ratio will be calculated by dividing the values obtained previously in the maximum isometric strength test of the hamstrings by those obtained in the quadriceps test. The value closer to 1, the greater the balance between the hamstrings and quadriceps muscles.
After the intervention (4 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Valencia

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Elena Marqués Sulé, Dr, Univeristy of Valencia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 30, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 2, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 2, 2023

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 11, 2023

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 11, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 2, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IE1541414

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings